Genetic_JJ
evidence_NN
for_IN
an_DT
additional_JJ
factor_NN
required_VBN
for_IN
erythropoietin-induced_JJ
signal_NN
transduction_NN
._.

Erythropoietin_NN
-LRB-_-LRB-
EPO_NN
-RRB-_-RRB-
and_CC
its_PRP$
receptor_NN
-LRB-_-LRB-
EPOR_NN
-RRB-_-RRB-
are_VBP
required_VBN
for_IN
the_DT
development_NN
of_IN
mature_JJ
erythrocytes_NNS
._.

After_IN
binding_NN
of_IN
ligand_NN
,_,
the_DT
EPOR_NN
activates_VBZ
a_DT
variety_NN
of_IN
signaling_NN
pathways_NNS
that_WDT
ultimately_RB
control_VBP
cellular_JJ
proliferation_NN
,_,
survival_NN
,_,
and_CC
specific_JJ
gene_NN
expression_NN
._.

Although_IN
erythroid_JJ
progenitors_NNS
appear_VBP
to_TO
be_VB
the_DT
principal_JJ
EPO-responsive_JJ
cell_NN
type_NN
in_FW
vivo_FW
due_JJ
to_TO
the_DT
restricted_JJ
expression_NN
of_IN
the_DT
EPOR_NN
,_,
many_JJ
growth_NN
factor-dependent_JJ
cell_NN
lines_NNS
expressing_VBG
the_DT
EPOR_NN
can_MD
respond_VB
to_TO
EPO_NN
by_IN
activating_VBG
many_JJ
or_CC
all_DT
of_IN
these_DT
pathways_NNS
._.

In_IN
the_DT
present_JJ
study_NN
,_,
we_PRP
have_VBP
identified_VBN
a_DT
cellular_JJ
context_NN
-LRB-_-LRB-
the_DT
interleukin-2_NN
-LCB-_-LRB-
IL-2_NN
-RCB-_-RRB-
-_:
dependent_JJ
HT-2_NN
line_NN
-RRB-_-RRB-
in_IN
which_WDT
the_DT
EPO_NN
stimulation_NN
of_IN
the_DT
EPOR_NN
fails_VBZ
to_TO
support_VB
cellular_JJ
proliferation_NN
,_,
STAT-5_NN
induction_NN
,_,
or_CC
MAPK_NN
activation_NN
,_,
despite_IN
efficient_JJ
phosphorylation_NN
of_IN
the_DT
EPOR_NN
and_CC
JAK2_NN
and_CC
inhibition_NN
of_IN
apoptosis_NN
after_IN
withdrawal_NN
of_IN
IL-2_NN
._.

Interestingly_RB
,_,
when_WRB
we_PRP
fused_VBD
HT-2_NN
cells_NNS
expressing_VBG
the_DT
EPOR_NN
with_IN
Ba\/F3_NN
cells_NNS
in_IN
a_DT
complementation_NN
assay_NN
,_,
the_DT
resulting_VBG
hybridomas_NNS
proliferated_VBD
and_CC
potently_RB
activated_VBD
STAT-5_NN
and_CC
MAPK_NN
in_IN
response_NN
to_TO
EPO_NN
._.

These_DT
data_NNS
indicate_VBP
that_IN
an_DT
unidentified_JJ
cellular_JJ
factor_NN
is_VBZ
needed_VBN
to_TO
mediate_VB
signaling_NN
by_IN
the_DT
EPOR_NN
._.

Moreover_RB
,_,
Ba\/F3_NN
cells_NNS
apparently_RB
express_VBP
this_DT
factor_NN
-LRB-_-LRB-
s_NNS
-RRB-_-RRB-
and_CC
somatic_JJ
fusions_NNS
can_MD
,_,
therefore_RB
,_,
confer_VB
EPO-responsiveness_NN
to_TO
HT-2_NN
cells_NNS
that_WDT
lack_VBP
this_DT
factor_NN
._.

